Asenapine
- TRADE NAME: Saphris (Merck)
- INDICATIONS: Schizophrenia, bipolar disorder
- CLASS: Antipsychotic
- HALF-LIFE: 24 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Alcohol, Amiodarone, Chlorpromazine, CYP2D6 substrates and inhibitors, Fluvoxamine, Gatifloxacin, Moxifloxacin, Paroxetine Hydrochloride, Procainamide, QT prolonging drugs, Quinidine, Sotalol, Thioridazine, Ziprasidone
PREGNANCY CATEGORY: C
INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS
See full prescribing information for complete boxed warning.
Please login to see the rest of this drug profile
SKIN.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
OTHER.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of asenapine in the Informa Healthcare journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 07/31/2023
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric